- Home
- RYAM vs FHTX Comparison
RYAM vs FHTX Comparison
Compare RYAM & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYAM
- FHTX
- Stock Information
- Founded
- RYAM 1926
- FHTX 2015
- Country
- RYAM United States
- FHTX United States
- Employees
- RYAM N/A
- FHTX N/A
- Industry
- RYAM Paper
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- RYAM Basic Materials
- FHTX Health Care
- Exchange
- RYAM Nasdaq
- FHTX Nasdaq
- Market Cap
- RYAM 577.2M
- FHTX 513.7M
- IPO Year
- RYAM N/A
- FHTX 2020
- Fundamental
- Price
- RYAM $8.91
- FHTX $7.72
- Analyst Decision
- RYAM Buy
- FHTX Strong Buy
- Analyst Count
- RYAM 1
- FHTX 5
- Target Price
- RYAM $12.00
- FHTX $16.00
- AVG Volume (30 Days)
- RYAM 654.9K
- FHTX 131.6K
- Earning Date
- RYAM 11-05-2024
- FHTX 11-04-2024
- Dividend Yield
- RYAM N/A
- FHTX N/A
- EPS Growth
- RYAM N/A
- FHTX N/A
- EPS
- RYAM N/A
- FHTX N/A
- Revenue
- RYAM $1,630,290,000.00
- FHTX $25,515,000.00
- Revenue This Year
- RYAM $0.53
- FHTX N/A
- Revenue Next Year
- RYAM $2.60
- FHTX $8.77
- P/E Ratio
- RYAM N/A
- FHTX N/A
- Revenue Growth
- RYAM N/A
- FHTX N/A
- 52 Week Low
- RYAM $3.02
- FHTX $2.70
- 52 Week High
- RYAM $10.28
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- RYAM 52.06
- FHTX 42.02
- Support Level
- RYAM $7.91
- FHTX $7.33
- Resistance Level
- RYAM $10.28
- FHTX $9.33
- Average True Range (ATR)
- RYAM 0.40
- FHTX 0.72
- MACD
- RYAM -0.06
- FHTX -0.13
- Stochastic Oscillator
- RYAM 39.11
- FHTX 16.46
About RYAM Rayonier Advanced Materials Inc.
Rayonier Advanced Materials Inc manufactures high-purity cellulose derived from wood. Also known as cellulose specialties, the company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, High-Yield Pulp, and Corporate and Other. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of revenue from the United States.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.